المساهمون: Chen-Lu Geng, Jun-Yi Chen, Tian-Yu Song, Jae Hyung Jung, Min Long, Min-Fang Song, Tong Ji, Byung Soh Min, Jin Gu Lee, Bo Peng, Yi-Sheng Pu, Hong-Jie Fan, Piliang Hao, Qi Zhou, Eui-Cheol Shin, Yong Cang, Min, Byung Soh

مصطلحات موضوعية: Animals, CD28 Antigens, CD8-Positive T-Lymphocytes, Immunologic Factors, Immunotherapy / methods, Lenalidomide / pharmacology, Mice, Programmed Cell Death 1 Receptor, CD28, CRBN, Notch signaling, PD-1, immunotherapy, lenalidomide

Relation: CELL CHEMICAL BIOLOGY; J00479; OAK-2022-10550; OAK-2022-10551; https://ir.ymlib.yonsei.ac.kr/handle/22282913/193422; https://www.sciencedirect.com/science/article/pii/S2451945622002045; T9992022651; CELL CHEMICAL BIOLOGY, Vol.29(8) : 1260-1272, 2022-08

الاتاحة: https://ir.ymlib.yonsei.ac.kr/handle/22282913/193422
https://doi.org/10.1016/j.chembiol.2022.05.012
https://www.sciencedirect.com/science/article/pii/S2451945622002045

المؤلفون: Hecht, Anna, Meyer, Julia A., Jann, Johann-Christoph, Sockel, Katja, Giagounidis, Aristoteles, Götze, Katharina S., Letsch, Anne, Haase, Detlef, Schlenk, Richard F., Haferlach, Torsten, Schafhausen, Philippe, Bug, Gesine, Lübbert, Michael, Thol, Felicitas, Büsche, Guntram, Schuler, Esther, Nowak, Verena, Obländer, Julia, Fey, Stephanie, Müller, Nadine, Metzgeroth, Georgia, Hofmann, Wolf-Karsten, Germing, Ulrich, Nolte, Florian, Reinwald, Mark, Nowak, Daniel

المصدر: http://lobid.org/resources/99370678538206441#!, 100(6):1463-1471.

مصطلحات موضوعية: Myelodysplastic syndromes, Deletion 5q, Female [MeSH], Aged, 80 and over [MeSH], Chromosomes, Human, Pair 5/genetics [MeSH], Aged [MeSH], DNA Methylation/drug effects [MeSH], Adult [MeSH], Humans [MeSH], Lenalidomide, Treatment Outcome [MeSH], Antineoplastic Agents/pharmacology [MeSH], Middle Aged [MeSH], Myelodysplastic Syndromes/genetics [MeSH], Original Article, Male [MeSH], Myelodysplastic Syndromes/drug therapy [MeSH], Antineoplastic Agents/therapeutic use [MeSH], Chromosome Deletion [MeSH], DNA methylation, Lenalidomide/pharmacology [MeSH], Lenalidomide/therapeutic use [MeSH]

Relation: https://repository.publisso.de/resource/frl:6447833; https://doi.org/10.1007/s00277-021-04492-1; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116243/

الاتاحة: https://repository.publisso.de/resource/frl:6447833
https://doi.org/10.1007/s00277-021-04492-1
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116243/

المساهمون: Ki Sun Jung, Kihyun Kim, Hyo Jung Kim, Sung Hyun Kim, Jeong-Ok Lee, Jin Seok Kim, Je-Jung Lee, Hyeon-Seok Eom, Chang-Ki Min, Ho-Jin Shin, Kim, Jin Seok

مصطلحات موضوعية: Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols / pharmacology, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Bortezomib / pharmacology, Bortezomib / therapeutic use, Dexamethasone / pharmacology, Dexamethasone / therapeutic use, Female, Humans, Lenalidomide / pharmacology, Lenalidomide / therapeutic use, Male, Middle Aged, Multiple Myeloma / drug therapy, Neoplasm Recurrence, Local, Retrospective Studies, Thalidomide / pharmacology, Thalidomide / therapeutic use, Treatment Outcome, Lenalidomide, Multiple myeloma, Refractory, Relapsed, Thalidomide

Relation: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA; J04262; OAK-2022-03880; https://ir.ymlib.yonsei.ac.kr/handle/22282913/190217; https://www.sciencedirect.com/science/article/pii/S2152265019320658; T9992020442; CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Vol.20(2) : E97-E104, 2020-02

الاتاحة: https://ir.ymlib.yonsei.ac.kr/handle/22282913/190217
https://doi.org/10.1016/j.clml.2019.10.017
https://www.sciencedirect.com/science/article/pii/S2152265019320658

المؤلفون: Wu, W., Nelson, G.M., Koch, R., Donovan, K.A., Nowak, R.P., Heavican-Foral, T.B., Nirmal, A.J., Liu, H., Yang, L., Duffy, J., Powers, F., Stevenson, K.E., Jones, M.K., Ng, S.Y., Wu, G., Jain, S., Xu, R., Amaka, S., Trevisani, C., Donaldson, N.L., Hagner, P.R., de Leval, L., Gaulard, P., Iqbal, J., Thakurta, A., Fischer, E.S., Adelman, K., Weinstock, D.M.

المصدر: Blood, vol. 139, no. 13, pp. 2024-2037

مصطلحات موضوعية: Drug Resistance, Neoplasm, Humans, Ikaros Transcription Factor/metabolism, Immunologic Factors/pharmacology, Lenalidomide/pharmacology, Lymphoma, T-Cell/drug therapy, Multiple Myeloma/drug therapy, Thalidomide/analogs & derivatives, Thalidomide/pharmacology, Ubiquitin-Protein Ligases/metabolism, Ubiquitination

Relation: info:eu-repo/semantics/altIdentifier/pmid/34936696; info:eu-repo/semantics/altIdentifier/eissn/1528-0020; https://serval.unil.ch/notice/serval:BIB_AA8497976701

الاتاحة: https://serval.unil.ch/notice/serval:BIB_AA8497976701
https://doi.org/10.1182/blood.2021014701

المؤلفون: Dirk Hose, Laurie Herviou, Carsten Müller-Tidow, Laure Vincent, Jérôme Moreaux, Giacomo Cavalli, Nicolas Robert, Guilhem Requirand, Hartmut Goldschmidt, Stéphanie Boireau, Anja Seckinger, Alboukadel Kassambara, Guillaume Cartron

المساهمون: Institut de génétique humaine (IGH), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Heidelberg University, Service d'hématologie et oncologie médicale, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie-Université de Montpellier (UM), Université de Montpellier (UM), Hematology, Basic (bio-) Medical Sciences

المصدر: Clinical Epigenetics
Clinical Epigenetics, BioMed Central, 2018, 10, pp.121. ⟨10.1186/s13148-018-0554-4⟩
Clinical Epigenetics, Vol 10, Iss 1, Pp 1-18 (2018)

مصطلحات موضوعية: 0301 basic medicine, Methyltransferase, lcsh:Medicine, Plasma cell, Drug Resistance, Neoplasm/drug effects, Epigenesis, Genetic, Predictive score, Cell Proliferation/drug effects, Multiple myeloma, Medicine, Lenalidomide, Genetics (clinical), DNA methylation, hematology, EZH2, Polycomb Repressive Complex 2, Drug Synergism, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, PRC2, 3. Good health, Gene Expression Regulation, Neoplastic, medicine.anatomical_structure, Benzamides, Epigenetics, Polycomb Repressive Complex 2/drug effects, lcsh:QH426-470, Tumor suppressor gene, Pyridones, Morpholines, Multiple Myeloma/drug therapy, [SDV.CAN]Life Sciences [q-bio]/Cancer, macromolecular substances, Lenalidomide/pharmacology, 03 medical and health sciences, Cell Line, Tumor, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Genetics, Humans, Molecular Biology, B cell, Cell Proliferation, Pyridones/pharmacology, business.industry, Sequence Analysis, RNA, Research, Gene Expression Profiling, lcsh:R, Biphenyl Compounds, Benzamides/pharmacology, medicine.disease, lcsh:Genetics, 030104 developmental biology, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic/drug effects, Cancer research, business, Developmental Biology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68e234ed8dfc79eca680e53893ff443b
https://hal.archives-ouvertes.fr/hal-02315111/file/s13148-018-0554-4.pdf